The American Journal of Medicine
Volume 118, Issue 12, Supplement 2 , Pages 136-141 , 19 December 2005

Breast cancer, menopause, and long-term survivorship: critical issues for the 21st century

  • Patricia A. Ganz, MD

      Affiliations

    • Corresponding Author InformationRequests for reprints should be addressed to Patricia A. Ganz, MD, Division of Cancer Prevention & Control Research, Jonsson Comprehensive Cancer Center, 650 Charles Young Drive South, Room A2-125 CHS, Los Angeles, California 90095-6900.

  • Image Result

    Percentage of breast cancer survivors (n = 1, 098) reporting hot flashes, night sweats, and vaginal discharge according to type of adjuvant therapy (Rx), assessed about 3 years after diagnosis. All st

    Percentage of breast cancer survivors (n = 1, 098) reporting hot flashes, night sweats, and vaginal discharge according to type of adjuvant therapy (Rx), assessed about 3 years after diagnosis. All statistical comparisons were adjusted for age and time since diagnosis, and all tests were done using likelihood ratio χ2 tests based on logistic regressions with and without treatment indicators. Frequencies presented are unadjusted for age and time since diagnosis. *For all values, P <0.0001. Chem = chemotherapy; Tam = tamoxifen. (Adapted from Recent Results Cancer Res.29)

  • Image Result
    Percentage of breast cancer survivors (n = 1, 098) reporting vaginal dryness, dyspareunia, and weight gain according to type of adjuvant therapy (Rx), assessed about 3 years after diagnosis. All stati

    Percentage of breast cancer survivors (n = 1, 098) reporting vaginal dryness, dyspareunia, and weight gain according to type of adjuvant therapy (Rx), assessed about 3 years after diagnosis. All statistical comparisons were adjusted for age and time since diagnosis, and all tests were done using likelihood ratio χ2 tests based on logistic regressions with and without treatment indicators. Frequencies presented are unadjusted for age and time since diagnosis. *For all values, P <0.01. Chem = chemotherapy; Tam = tamoxifen. (Adapted from Recent Results Cancer Res.29)

 The opinions offered at the National Institutes of Health (NIH) State-of-the Science Conference on Management of Menopause-Related Symptoms and published herein are not necessarily those of the National Institute on Aging (NIA) and the Office of Medical Applications of Research (OMAR) or any of the cosponsoring institutes, offices, or centers of the NIH. Although the NIA and OMAR organized this meeting, this article is not intended as a statement of Federal guidelines or policy.Publication of the online supplement was made possible by funding from the NIA and the National Center for Complementary and Alternative Medicine of the NIH, US Department of Health & Human Services.Supported in part by an American Cancer Society Clinical Research Professorship awarded to Dr. Ganz.

PII: S0002-9343(05)00905-8

doi: 10.1016/j.amjmed.2005.09.047

The American Journal of Medicine
Volume 118, Issue 12, Supplement 2 , Pages 136-141 , 19 December 2005

Article Tools

* Image Usage & Resolution